Press release



# GenSight Biologics to Attend Upcoming Investor Conferences

**Paris, France, April 19, 2017, 7.30 CET** – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that members of its management team will attend the following investor conferences:

## 5<sup>th</sup> Annual ARM Cell & Gene Investor Day

April 27, 2017 – Boston, MA

Bernard Gilly, Chief Executive Officer, will present on April 27, 2017, at 4:45pm EST, at The State Room.

## Deutsche Bank 42<sup>nd</sup> Annual Health Care Conference

#### May 3-4, 2017 - Boston, MA

Bernard Gilly, Chief Executive Officer, will present on May 4, 2017, at 9:20am EST, at the InterContinental Boston Hotel.

#### Contacts

GenSight Biologics Thomas Gidoin Chief Financial Officer tgidoin@gensight-biologics.com +33 (0)1 76 21 72 20 RooneyPartners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017 The Trout Group Investor Relations Chad Rubin <u>crubin@troutgroup.com</u> +1-646-378-2947

### About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber's Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.